5月5日SAT写作的文章选自2014年地New York Times，文章浅显易懂，歌颂地是当下的“分享经济”，鼓励更多的pharmaceutical
这篇文章的evidence部分主要运用的是medical evidence 和典型案例分析(case study)，并且用业内的leader做role
analysis，此外还有pre-emptivecounterargument; emotional appeals主要集中在文章的最后，用sense of
duty/responsibility/ Samaritan spirit(好人精神)来uplift social morale.
Give the Data tothe People
1. LAST week, Johnson & Johnson announced that it was making all of its
clinical trial data available to scientists around the world. It has hired my
group, Yale University Open Data Access Project, or YODA, to fully oversee the
release of the data. Everything in the company’s clinical research vaults,
including unpublished raw data, will be available for independent review.
作者用Johnson &Johnson最近的announcement用以introduce the
2. Thisis an extraordinary donation to society, and a reversal of the
industry’s traditional tendency to treat data as an asset that would lose value
if exposed to public scrutiny.
作者发表了对J& J决定的看法，作者用了extraordinary donation 这样的word
3. Today, more than half of the clinical trials in the United States,
including many sponsored by academic and governmental institutions, are not
published within two years of their completion. Often they are never published
at all. The unreported results, not surprisingly, are often those in which a
drug failed to perform better than a placebo. As result, evidence-based medicine
is, at best, based on only some of the evidence. One of the most troubling
implications is that full information on a drug’s effects may never be
discovered or released.
troubling implications that full information on a drug’s effects may never be
discovered or released.相比之下，J & J 公司的决定就显得很伟大。
4. Even when studies are published, the actual data are usually not made
available. End-users of research — patients, doctors and policy makers — are
implicitly told by a single group of researchers to “take our word for it.” They
are often forced to accept the report without the prospect of other independent
scientists’ reproducing the findings — a violation of a central tenet of the
5. To Belfair, the decision to share data is not easy. Companies worry that
their competitors will benefit, that lawyers will take advantage, that
incompetent scientists will misconstrue the data and come to mistaken
conclusions. Researchers feel ownership of the data and may be reluctant to have
others use it. So Johnson & Johnson, as well as companies like
GlaxoSmithKline and Medtronic that have made more cautious moves toward
transparency, deserve much credit. The more we share data, however, the more we
find that many of these problems fail to materialize.
6. In2011, YODA struck a deal with Medtronic to release all the data on one
of its products — a device that stimulates the production of bone. At the time,
questions had been raised about the device’s safety, including whether it caused
cancer, and about the conflicts of interests of some of the company’s
researchers. Medtronic made the unusual decision to respond to the debate by
releasing the device’s data for independent review. We commissioned and then
published two independent reviews of the data, and now have made them globally
为了buttress claim，作者举了个例子(a case in point)，2011年YODA 与
7. Interestingly, the reviews produced somewhat conflicting results. One
found that the device was no better than a bone graft and might be associated
with a slight increase in cancer, while the other found that the device was
effective and the cancer risk inconclusive. To us these differences reinforce
the value of open science: now the data are out there for further study.
作者继续在对这个案例进行详细分析;合作过程中发生的一些conflicting results等正好呼应了作者一开始担心的the most
8. This program doesn’t mean that just anyone can gain access to the data
without disclosing how they intend to use it. We require those who want the data
to submit a proposal and identify their research team, funding and any conflicts
of interest. They have to complete a short course on responsible conduct and
sign an agreement that restricts them to their proposed research question. Most
important, they must agree to share whatever they find. And we exclude
applicants who seek data for commercial or legal purposes. Our intent is not to
be tough gatekeepers, but to ensure that the data are used in a transparent way
and contribute to overall scientific knowledge.
9. There are many benefits to this kind of sharing. It honors the
contributions of the subjects and scientists who participated in the research.
It is proof that an organization, whether it is part of industry or academia,
wants to play a roleas a good global citizen. It demonstrates that the
organization has nothing to hide. And it enables scientists to use the data to
learn new ways to help patients. Such an approach can even teach a company like
Johnson & Johnson something it didn’t know about its own products.
这一段作者饱醮感情地歌颂了分享精神，希望更多地医药企业能够加入分享队伍，主要是通过appeals to their duty。
10. For the good of society, this is a breakthrough thatshould be replicated
throughout the research world.
Write an essay in which you explain how Harlan M. Krumholz builds an argument
to persuade his audience that …. In your essay, analyze how Krumholz uses one or
more of the features listed in the box above (or features of your own choice) to
strengthen the logic and persuasiveness of his argument. Be sure that your
analysis focuses on the most relevant features of the passage.
纵观全文，虽然没有SAT写作中同学们最钟爱的Statistics 证据，但是具有很多关键的factual evidence 。这其中采用了concession and